Insulin giant Novo Nordisk (NYSE:NVO) has reportedly approached Global Blood Therapeutics (NSDQ:GBT) to discuss a possible takeover. The U.S. biotech is reviewing its options with an investment bank, according to Reuters, and there is no guarantee that it will enter formal negotiations with Novo Nordisk. Global Blood Therapeutics is developing GBT440, a once-daily, oral therapy to treat […]
Mergers & Acquisitions
Azaya Therapeutics bought by Cytori, nanoparticle program launched
Cytori Therapeutics (NSDQ:CYTX) said yesterday that it completed its acquisition of San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs. In late January, San Diego-based Cytori said it planned to buy Azaya in a stock deal, offering Azaya shareholders $2 million in CTYX stock. Cytori also said that it paid $2 million upfront for costs associated […]
How Sanofi blew its chance with Actelion
Days before entering into exclusive takeover negotiations with Johnson & Johnson (NYSE:JNJ), Actelion (VTX:ATLN) was reportedly fielding an offer from Sanofi (NYSE:SNY). But the Swiss biotech eventually agreed to go with J&J’s $30 billion bid in an all-cash deal at the end of January. Actelion accepted the U.S. healthcare giant’s offer because it provided more certainty, Reuters reported today. The prospectus […]
Catalent acquires soft-gel manufacturer Accucaps
Catalent (NYSE:CTLT) said today that it closed its acquisition of Canada-based Accucaps and its pharmaceutical soft-gel manufacturing capabilities. The Somerset, N.J.-based company did not disclose the deal’s financial details. In November last year, Catalent said that it planned to fund the Accucaps buy with a $400 million debt offering. The company also plans to use the private placement […]
Allergan acquires Zeltiq Aesthetics in $2.48B deal
Allergan (NYSE:AGN) said today that it will pay $2.48 billion for Zeltiq Aesthetics Inc. (NSDQ:ZLTQ) and its portfolio of body-contouring products. Zeltiq’s FDA-approved CoolSculpting system uses a cooling mechanism to reduce the appearance of fat which has not responded to diet or exercise, without disturbing surrounding tissue. According to the deal, Allergan agreed to pay […]
How Trelleborg is getting the most out of its acquisitions—including with combo devices
Heather Thompson, Senior Editor As is the case with many medical device industry suppliers, Trelleborg has engaged in a spate of acquisitions to better serve the growing needs of its OEM customers for drug-device combo products and more. Last year, Trelleborg, Sweden–based Trelleborg announced the acquisition of Tustin, California–based Specialty Silicone Fabricators. They’ve made three […]
Allergan closes $3B Acelity LifeCell buy
Acelity said today that it closed the sale of its regenerative medicine unit, LifeCell, to Allergan (NYSE:AGN) for $2.9 billion in cash. The deal brings LifeCell’s regenerative medicine and reconstructive portfolio to Allergan, joining a portfolio of medical aesthetics, breast implant and tissue expander product lines. Dublin-based Allergan said it expects to bring in $450 million in revenue this year, growing […]
Celgene acquires Delinia, beats on Q4 earnings
Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results. The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth […]
Johnson & Johnson to pay $30B for Actelion
After weeks of exclusive negotiations, Johnson & Johnson (NYSE:JNJ) said on Thursday that it plans to buy Swiss biotech firm Actelion (VTX:ATLN) for $30 billion in an all-cash deal. The companies have reportedly been in talks for months – Sanofi (NYSE:SNY) was also involved in discussions for Actelion, but was sidelined after J&J entered into exclusive negotiations with Actelion last […]
J&J, Actelion still in talks despite Opsumit failure
Although Actelion (VTX:ATLN)’s Opsumit drug candidate missed its primary endpoint in a phase III trial for patients suffering from a deadly heart-lung condition, analysts reportedly concluded that the result is unlikely to have an impact on merger talks with Johnson & Johnson (NYSE:JNJ). The Swiss drugmaker’s trial involved 226 patients with Eisenmenger Syndrome, which causes untreated congenital heart […]
